Fosun Pharma (600196.SH, 02196.HK) Gains Approval for Clinical Trial of FXS0887

Bulletin Express12-03

On 3 December 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, received approval from the National Medical Products Administration to commence the Phase I clinical trial of FXS0887 in China. This orally administered small molecule drug specifically targets ATR kinase activity and is intended for the treatment of advanced malignant solid tumors. According to the announcement, approximately RMB44 million had been invested in this research project as of October 2025.

Preclinical studies of FXS0887 indicated notable anti-tumor efficacy, low off-target risk, and favorable safety profiles. Currently, there is no monotherapy or combination therapy regimen with the same target approved for marketing worldwide. The announcement also highlights that drug research and development is a long-term effort with uncertainties and risks, including the potential for trial discontinuation based on safety or efficacy issues.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159062522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 18:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159062522","market":"us","top_or_hot":-1,"title":"Fosun Pharma (600196.SH, 02196.HK) Gains Approval for Clinical Trial of FXS0887","media":"Bulletin Express","content":"<p>On 3 December 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, received approval from the National Medical Products Administration to commence the Phase I clinical trial of FXS0887 in China. This orally administered small molecule drug specifically targets ATR kinase activity and is intended for the treatment of advanced malignant solid tumors. According to the announcement, approximately RMB44 million had been invested in this research project as of October 2025.</p>\n<p>Preclinical studies of FXS0887 indicated notable anti-tumor efficacy, low off-target risk, and favorable safety profiles. Currently, there is no monotherapy or combination therapy regimen with the same target approved for marketing worldwide. The announcement also highlights that drug research and development is a long-term effort with uncertainties and risks, including the potential for trial discontinuation based on safety or efficacy issues.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (600196.SH, 02196.HK) Gains Approval for Clinical Trial of FXS0887</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (600196.SH, 02196.HK) Gains Approval for Clinical Trial of FXS0887\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-03 18:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 3 December 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, received approval from the National Medical Products Administration to commence the Phase I clinical trial of FXS0887 in China. This orally administered small molecule drug specifically targets ATR kinase activity and is intended for the treatment of advanced malignant solid tumors. According to the announcement, approximately RMB44 million had been invested in this research project as of October 2025.</p>\n<p>Preclinical studies of FXS0887 indicated notable anti-tumor efficacy, low off-target risk, and favorable safety profiles. Currently, there is no monotherapy or combination therapy regimen with the same target approved for marketing worldwide. The announcement also highlights that drug research and development is a long-term effort with uncertainties and risks, including the potential for trial discontinuation based on safety or efficacy issues.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1159062522","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159062522","pubTimestamp":1764756537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 3 December 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, received...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药（600196.SH，02196.HK）获得FXS0887临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"On 3 December 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, received approval from the National Medical Products Administration to commence the Phase I clinical trial of FXS0887 in China. This orally administered small molecule drug specifically targets ATR kinase activity and is intended for the treatment of advanced malignant solid tumors. According to the announcement, approximately RMB44 million had been invested in this research project as of October 2025.\nPreclinical studies of FXS0887 indicated notable anti-tumor efficacy, low off-target risk, and favorable safety profiles. Currently, there is no monotherapy or combination therapy regimen with the same target approved for marketing worldwide. The announcement also highlights that drug research and development is a long-term effort with uncertainties and risks, including the potential for trial discontinuation based on safety or efficacy issues.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159062522","isCrawlerRequest":true}